(Androblastoma; Sertoli-Leydig Cell Tumor of the Ovary)
An arrhenoblastoma is a rare type of ovarian tumor, which primarily secretes the male sex hormone, testosterone, and rarely the female sex hormone, estrogen. It accounts for less than 0.5% of all ovarian tumors.
Arrhenoblastomas are generally benign, meaning they do not normally spread beyond the ovary. However, they may cause male physical characteristics to develop in women, such as facial hair and a deepening voice. If you suspect you have this condition, contact your doctor immediately.
A risk factor is something that increases your chance of getting a disease or condition. The following factors increase your chance of developing arrhenoblastoma. If you have any of these risk factors, tell your doctor:
- Being female
- Young age—arrhenoblastomas most commonly occur among young women (ages 20-30), however they may occur at any age, including toddlers, young girls, and postmenopausal women
- Very rarely, arrhenoblastoma is a complication of pregnancy
If you experience any of these symptoms, do not assume it is due to an arrhenoblastoma. These symptoms may be caused by other, less serious health conditions. If you experience any one of them, see your physician.
Your doctor will ask about your symptoms and medical history, and perform a physical exam. He or she will also test your levels of male hormones (such as testosterone and androsterone) to see if they are excessive.
Tests may include the following:
- Blood tests of hormone levels (including testosterone, DHEA, CD56, and progesterone levels)—to detect if male hormones are high
Treatment involves surgery to remove one or both ovaries. This procedure is usually successful in returning normal menstruation (in premenopausal women) and ceasing masculinization. If the tumor is late stage and particularly aggressive (which is rare), radiation therapy
There are no known ways to prevent ovarian cancer of any kind, as the cause is unknown. To learn more about risk factors for ovarian cancers in general, see the fact sheet on ovarian cancer
The Endocrine Society
Ovarian Cancer National Alliance
National Ovarian Cancer Association
Ovarian Cancer Canada
Chen F, Sheu B, Lin M, Chow S, Lin H. Sertoli-leydig cell tumor of the ovary. J Formos Med Assoc . Available at: http://cat.inist.fr/?aModele=afficheN&cpsidt=17460145 . Accessed November 30, 2006.
Choong S, Fuller P, Chu S, Jeske Y, Bowling FRB, Borzi P, et al. Sertoli-Leydig cell tumor of the ovary, a rare cause of precocious puberty in a 12-month-old infant. J Clin Endocrinol Metab . 2002;87:49-56. Available at: http://jcem.endojournals.org/cgi/content/full/87/1/49?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=Sertoli-Leydig+&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT . Accessed Nov.28, 2006.
Colombo N, Parma G, Zanagnolo V, Insinga A: Management of Ovarian Stromal Cell Tumors. J Clin Oncol . 2007;20:2944-51.
McCluggage WG, McKenna M, McBride HA 2007 CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord stromal tumor. INt J Gyn Pathol. 26:322-7.
Sertoli-Leydig cell tumor. DynaMed website. Available at: http://dynamed102.epnet.com/Detail.aspx?style=1&docid=/dynamed/6ff6e9c652fcb92c852562ac004b1114. Accessed November 27, 2006.
Sex cord-stromal tumors. Johns Hopkins Pathology website. Available at: http://ovariancancer.jhmi.edu/stromal.cfm . Accessed November 27, 2006.
Last reviewed November 2008 by
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2007 EBSCO Publishing All rights reserved.